Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Exopharm identifies two new lead programs as exosomes gain prominence in gene therapy
Health & Biotech
Exopharm a LEAP ahead of competitors in emerging exosome medicine field
News
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Health & Biotech
How Exopharm LEAP technology is fuelling accelerated development of immune-silent, precision delivery of next-generation, exo-medicines
Health & Biotech
Exopharm and Astellas team up for exosomes evaluation
Health & Biotech
Exopharm secures US patent for exosomes purification technology
Health & Biotech
ASX Health Stocks: Lumos is ready to seek regulatory approval for its COVID-19 rapid antigen test
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Exopharm shares soar 12pc on Q1 update as LEAP tech promises to advance wide range of medicines
Health & Biotech
Exopharm appoints two key executives as it transitions into a global exosomes company
Health & Biotech
Exopharm signs deal with Japanese chemical company as LEAP tech promise to accelerate new cancer-beating research
News
ASX Health Stocks: Medical imaging player Resonance Health leads the pack with FY21 revenue increase
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Exopharm takes major step forward in global strategy with approval for its first national patent
Health & Biotech
$12m capital raising puts Exopharm in strong position to negotiate new partnerships
Health & Biotech
Pitt Street Research says Exopharm worth up to $4.71 a share
Health & Biotech
